113 FRAIL-AF RANDOMISED CONTROLLED TRIAL: RESULTS TABLE 1: PATIENT CHARACTERISTICS. Continue with VKA (n=661) Switch to NOAC (n=662) Demographics Female sex n (%) 239 (36.2%) 274 (41.4%) Age in years mean (SD) 82.8 (5.1) 83.0 (5.1) Groningen Frailty Indicator Groningen Frailty Indicator score median (IQR) 4 (3-6) 4 (3-6) Groningen Frailty Indicator 3 n (%) 171 (25.9%) 170 (25.7%) Groningen Frailty Indicator ≥4 n (%) 490 (74.0%) 492 (74.3%) Groningen Frailty Indicator (specific domains) Use of ≥4 different types of medication n (%) 581 (87.9) 589 (89%) Complaints of memory n (%) 261 (39.5%) 237 (35.8%) Unable to walk around the house n (%) 112 (16.9%) 112 (16.9%) Problems due to impaired vision n (%) 279 (42.2%) 297 (44.9%) Problems due to impaired hearing n (%) 353 (53.4%) 380 (57.4%) Atrial fibrillation Duration of atrial fibrillation in years mean (SD) 13.0 (9.9) 12.0 (9.2) Paroxysmal atrial fibrillation n (%) 201 (30.4%) 170 (25.7%) Persistent atrial fibrillation n (%) 57 (8.6%) 63 (9.5%) Permanent atrial fibrillation n (%) 335 (50.7%) 340 (52.7%) Unknown n (%) 68 (10.3%) 89 (13.4%) Medical history Heart failure n (%) 150 (22.7%) 129 (19.5%) Hypertension n (%) 336 (50.8%) 365 (55.1%) Diabetes mellitus n (%) 140 (21.2%) 140 (21.1%) History of major bleeding n (%) 88 (13.3%) 105 (15.9%) History of thromboembolic event n (%) 117 (17.7%) 139 (21.0%) Active cancer n (%) 35 (5.3%) 44 (6.6%) Liver cirrhosis n (%) 5 (0.8%) 3 (0.5%) eGFR in mL/min/1.73 m2 mean (SD) 62.7 (15.6) 62.5 (15.8) Risc score CHA2DS2-VASc score median (IQR) 4.0 (3.0-5.0) 4.0 (3.0-5.0) Risk factor Body-mass index mean (SD) 27.4 (11.7) 27.4 (6.0) Medication Off-label reduced NOAC dose n (%) n.a. 44 (6.6%) Concurrent platelet inhibitor use n (%) 13 (2.0) 16 (2.4) eGFR: estimated glomerular filtration rate; IQR: interquartile range; n.a.: not applicable; NOAC: non-vitamin K antagonist oral anticoagulant; SD: standard deviation; VKA: vitamin K antagonist. 7
RkJQdWJsaXNoZXIy MTk4NDMw